366 results about "Fetus fetus" patented technology

Blood plasma of pregnant women contains fetal and (generally>90%) maternal circulatory extracellular DNA. Most of said fetal DNA contains ≦500 base pairs, said maternal DNA having a greater size. Separation of circulatory extracellular DNA of <500 base pairs results in separation of fetal from maternal DNA. A fraction of a blood plasma or serum sample of a pregnant woman containing, due to size separation (e.g. by chromatography, density gradient centrifugation or nanotechnological methods), extracellular DNA substantially comprising ≦500 base pairs is useful for non-invasive detection of fetal genetic traits (including the fetal RhD gene in pregnancies at risk for HDN; fetal Y chromosome-specific sequences in pregnancies at risk for X chromosome-linked disorders; chromosomal aberrations; hereditary Mendelian genetic disorders and corresponding genetic markers; and traits decisive for paternity determination) by e.g. PCR, ligand chain reaction or probe hybridization techniques, or nucleic acid arrays.

Blood plasma of pregnant women contains fetal and (generally>90%) maternal circulatory extracellular DNA. Most of said fetal DNA contains .Itoreq.500 base pairs, said maternal DNA having a greater size. Separation of circulatory extracellular DNA of .Itoreq.500 base pairs results in separation of fetal from maternal DNA. A fraction of a blood plasma or serum sample of a pregnant woman containing, due to size separation (e.g. by chromatography, density gradient centrifugation or nanotechnological methods), extracellular DNA substantially comprising .Itoreq.500 base pairs is useful for non-invasive detection of fetal genetic traits (including the fetal RhD gene in pregnancies at risk for HDN; fetal Y chromosome-specific sequences in pregnancies at risk for X chromosome-linked disorders; chromosomal aberrations; hereditary Mendelian genetic disorders and corresponding genetic markers; and traits decisive for paternity determination) by e.g. PCR, ligand chain reaction or probe hybridization techniques, or nucleic acid arrays.

Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.

The invention relates to a method of identifying fetal abnormality from a maternal blood sample by capturing an image of a fetal nucleated red blood cell obtained from the maternal blood sample; inputting probe intensities for a plurality of nucleic acid probes that bind fetal nucleic acids of interest; analyzing the probe intensities; and generating a diagnostic output according to results of the analysis. In some embodiments, the probes are specific to a chromosome.

The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a mixed sample of DNA comprising DNA from both the mother of the fetus and from the fetus, and optionally from genotypic data from the mother and father. The ploidy state is determined by using a joint distribution model to create a plurality of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. The mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias, for example using massively multiplexed targeted PCR.

The invention provides an overexpression porcine co-stimulatory 4-1BB vector and application thereof. PCR (polymerase chain reaction) amplification is performed on a left homologous arm and a right homologous arm of an intron 1 of a rosa26 gene, a 4-1BB regulatory sequence and an OCT4 specific promoter; the left homologous arm, a 4-1BB expression cassette, LoxP locus-contained Cre and Neo expression cassettes, the right homologous arm and negative selection DTA diphtheria toxin are connected in sequence to obtain a 4-1BB homologous recombinant vector p4BOCNDR; the vector and a CRISPR / Cas9 (clustered regularly interspaced short palindromic repeats / CRISPR-associated) targeting vector of sgRNA (small guide ribonucleic acid) containing the intron 1 of the specific targeting porcine rosa26 gene are transferred together into a porcine fetus fibroblast; by taking a positive cell as a donor cell and an oocyte as a recipient cell, a cloned embryo is obtained through a somatic cell nuclear transfer technique; the cloned embryo is transplanted into a porcine uterus for fetation to obtain a transgenic pig integrating a 4-1BB gene at the fixed point of a first intron of the rosa26 gene and automatically deleting a marker gene.

The present invention is directed to a new method for genotype determination at a specific gene locus of an individual or a fetus comprising (i) amplifying a first sequence of said gene locus and a second sequence of a second reference gene locus from DNA originating from a sample containing biological material of said individual or fetus (ii) Monitoring both amplifications preferably in real time and determining the amount of amplification products after each cycle, and (iii) Calculating the ratio between the amount of DNA from the first gene locus and the amount of DNA from the second gene locus. The new method is useful for a variety of applications, especially for detection of chromosomal abnormalities in fetal cells.

The present invention provides food bars for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant containing one or more vitamins and / or minerals, DHA, one or more DHA taste-masking agents and, optionally, one or more anti-constipation and regularity-maintaining agents, methods for preparing these food bars, and methods for supplementing the dietary requirements of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant. The food bars of the invention generally comprise one or more vitamins and minerals recommended for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant in an amount that is effective for enhancing the nutrition of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant, and that is not harmful to developing fetuses or breast-feeding babies, including calcium in an amount above 1,000 mg, DHA in an amount that is effective for providing, or increasing the supply of, DHA to a developing fetus or baby through a placenta or breast milk, one or more DHA taste-masking agents in an amount that is effective for masking the taste of DHA, and that is not harmful to developing fetuses or breast-feeding babies and, optionally, one or more anti-constipation and regularity-maintaining agents in an amount that is effective for reducing or eliminating constipation, and that is not harmful to developing fetuses or breast-feeding babies, from about 0 to about 99 weight percent of carbohydrates, from about 0 to about 80 weight percent of proteins, and from about 0 to about 60 weight percent of fats.

Maternal and fetal birthing simulators are disclosed. The maternal simulator has a rotatable pelvis, legs articulated at the hip and knee joints, and a deformable covering that simulates the feel of the skin and underlying tissues. The maternal birthing simulator may optionally be used with a pressure-based uterine propulsive system. The fetal simulator has an extensible spine, a movable head, movable clavicles, and arms articulated at the shoulder and elbow joints, and may include sensors to measure spinal extension, head rotation, applied traction force, and brachial plexus displacement. Fetal brachial plexus strain simulators and simulation methods are also disclosed.

The invention belongs to the medical detection field, and discloses a method and a system for noninvasive detection of fetus chromosome aneuploid. The disclosed detection method and system also relate to a method and a system for elimination of sequencing GC preference in chromosomes and among chromosomes and a method and a system used for the relation model of the Z values of X and Y chromosomes in a normal male fetus. Through elimination of influences of sequencing GC preference in chromosomes and among chromosomes, the relation model of the Z values of X and Y chromosomes in a normal male fetus is built, and the determination threshold of difference between the theoretical value and the actual value of the Z value of the X chromosome is built. The accurate detection of fetus chromosome aneuploid, especially sex chromosome aneuploid is achieved.

The invention relates to the field of treatment of biological and medical signals, in particular to a device for automatically identifying a fetal heart rate baseline and a method for realizing the device. The method provided by the invention comprises the steps of: collecting fetal heart rate data within a preset time length to obtain a fetal heart rate data series h'(n); preprocessing the collected fetal heart rate data series h'(n) to obtain respective fetal heart rate data series corresponding to the preprocessing process; selecting a main dominant peak value according to the frequency distribution of the respective fetal heart rate data series corresponding to the preprocessing process; and performing dynamic baseline identification according to the respective fetal heart rate data series corresponding to the preprocessing process and the main dominant peak value to obtain, display and print a dynamic baseline. According to the technical scheme of the device provided by the invention, the influence of regular changes of fetal heart rate on baseline solutions can be effectively avoided, and the baseline level and the changes thereof of a fetus under different conditions can beaccurately reflected.

Systems, methods, and apparatuses can determine and use methylation profiles of various tissues and samples. Examples are provided. A methylation profile can be deduced for fetal / tumor tissue based on a comparison of plasma methylation (or other sample with cell-free DNA) to a methylation profile of the mother / patient. A methylation profile can be determined for fetal / tumor tissue using tissue-specific alleles to identify DNA from the fetus / tumor when the sample has a mixture of DNA. A methylation profile can be used to determine copy number variations in genome of a fetus / tumor. Methylation markers for a fetus have been identified via various techniques. The methylation profile can be determined by determining a size parameter of a size distribution of DNA fragments, where reference values for the size parameter can be used to determine methylation levels. Additionally, a methylation level can be used to determine a level of cancer.

A method, system, and computer program product are provide for, among other things, quantitative analysis of heart rate characteristics from fetal heart rate and cardiotocogram monitors that gives information about the well-being of the fetus and the risk of poor fetal outcome. The method comprises (a) continuously measuring fetal heart rate and cardiotocographic characteristics and (b) identifying at least one characteristic abnormality in the heart rate characteristics that is associated with fetal distress. Benefits are appreciated by the fetus and the mother and during the antepartum and intrapartum periods.

A method for discriminating and recording the sex of fetus by ultrasonography B includes such steps as using the probe of ultrasonography B to obtain and display the image of fetus, recognizing the image for judging if it has sexual organ, and recording the sex of fetus if the display frequency of the fetus image containing sexual organ is higher than a predefined normal frequency.

The invention discloses a method for performing quality control on an ultrasonic section image of a fetus during middle and late pregnancy. The method comprises the following steps of: acquiring a section image of a certain part of a fetus, preprocessing the section image of the certain part of the fetus to obtain a pre-processed section image of the certain part of the fetus, inputting the pre-processed section image of the certain part of the fetus into a trained depth convolutional neural network to obtain the category of the section image of the certain part of the fetus, and key structures and position coordinates contained in the section image of the certain part of the fetus, directly outputting a 'standard section of the certain part' result if the category of the section image ofthe certain part of the fetus is standard, and directly outputting a 'non-standard section of the certain part' result and pointing out the reason of the nonstandard section if the category of the section image of the certain part of the fetus is nonstandard. The method generates a score and a quality evaluation report for the section image of the certain part of the fetus. The method can solve the technical problem that the prior method is difficult to be widely popularized and applied in actual clinic.

The invention belongs to the technical field of biological detection and relates to an African swine fever polymerase chain reaction (PCR) detection method and an oligonucleotide primer pair. The method comprises the following steps: designing a pair of specific primers by referring to a complete genome sequence of 23 ASFVP72 protein strains recorded in GenBank, exploring the optimal reaction system and reaction conditions according to the designed primers, performing sensitivity test, specificity test and reproducibility test on the established PCR reaction method, and performing PCR method detection on clinical samples of sows suffered from reproductive disturbance or piglets with respiratory disturbance symptoms and aborted fetuses from 14 pig farms. The test results prove that the established PCR method can sensitively and rapidly detect the African swine fever virus. The PCR detection method established in the research has high applicability and can be used for detecting the African swine fever disease.

The invention belongs to the field of biological medicines and discloses a method for rapidly and effectively acquiring an umbilical cord mesenchymal stem cell (MSC). The method is characterized in that the umbilical cord MSC is rapidly and effectively acquired by taking the umbilical cord of a newly born fetus as a resource and is rapidly identified by using an optimized umbilical cord tissue digestive enzyme formula and a digestive cell adherence mode. The method is developed by improvement based on the traditional MSC, the time for acquiring the MSC is shortened to the half of the traditional method, the yield is improved by one time, and various surface characteristics and functions of the MSC are not influenced. The invention provides the method for rapidly and effectively acquiring the MSC for the scientific researches and clinical application of the umbilical cord MSC.

A humanized antibody of the present invention shows similar antigen-binding affinity to a mouse monoclonal antibody and significantly low immunogenecity. Therefore, the humanized antibody of the present invention can be effectively used for treating chronic hepatitis B and preventing HBV infection of a patient received liver transplantation and vertical transmission from a mother infected with HBV to a fetus.

The present invention provides an improved ultrasound imaging system arranged to evaluate a set of acquired 3D image data in order to provide a compounded 3D image of a fetus irrespective of its position and movement. This is achieved by providing an ultrasound imaging system comprising: an ultrasound probe having an ultrasound transducer array operable to acquire at different look directions a plurality of three dimensional (3D) ultrasound image frames of a volumetric region comprising a fetus; a compound image memory for storing the acquired plurality of the 3D ultrasound image frames and an articulated fetal model with a common fetal structure; an ultrasound image processor responsive to the plurality of 3D ultrasound image frames, said processor comprising a fetal segmentation unit arranged to segment each 3D image frame based on the articulated fetal model thereby providing a plurality of spatially related 3D images of the volumetric region; and an image quality analyzer coupled to the segmentation unit and arranged to determine, based on the articulated fetal model, an overall confidence value of the plurality of the 3D images, said image quality analyzer is further arranged to compare the overall confidence value with an image compounding threshold.

The invention relates to a prenatal gene screening method for Down's syndrome by using nucleated erythrocyte and a kit thereof. The method is that a kit which comprises a nucleated erythrocyte purification reagent, primers and a bichrome Taqman fluorescent probe which are synthesized by the specific sequence DSCR section sequence of chromosome 21 and the GAPDH gene sequence on chromosome 16, and an amplification buffering action reagent of PCR action. The invention realizes that through the following steps: (a) the purification of fetus NRBC and the extraction of DNA; (b) the synthesis of the primers and the bichrome Taqman fluorescent probe respectively by using the specific sequence DSCR section sequence of chromosome 21 and the GAPDH gene sequence on chromosome 16; (c) the co-amplification of two pairs of the primers to obtain the curve of fluorescence quantitative PCR by the bichrome fluorescence quantitative PCR reaction in the amplification buffering reaction system. The invention has simple and convenient operation and high testing throughput, and belongs to a non-invasive prenatal diagnostic method.

The invention discloses a method for extracting fetus gene information. In the provided method, maternal cell DNA and acellular DNA are separated from a maternal sample, wherein the acellular DNA is from the fetus. Two DNA samples are strictly processed by same reagents and methods and subjected to parallel sequencing in a same sequencing reaction; and the fetus gene information and fetus gene abnormity can be obtained by comparing the sequencing results of two DNA samples. The provided autologous comparing method can be applied to detection of chromosome aneuploidy, and can also be applied to gene detections such as chimera detection, copy number variation detection, single point mutation detection, and the like.

The invention provides a noninvasive fetus 21, 18 and 13 trisomic syndrome antenatal detection positive quality control product and a preparing method thereof, and belongs to the fetus chromosome aneuploid noninvasive antenatal detection range. The preparing method of the positive quality control product includes the steps that DNAs of abortion groups of fetuses suffering from 21, 18 and 13 trisomic syndromes are broken into DNA fragments with the length ranging 160 bp to 200 bp; the abortion group DNA fragments recycled after breaking are added into mixed plasma in proportion; and the total plasma free DNAs are finally extracted, and the positive quality control products with different concentrations are prepared after attenuation with ultrapure water is carried out. The positive quality control product is a white transparent DNA solution, and has the beneficial effects of being stable, easy to store, convenient and rapid to use, non-toxic and the like; in addition, deviations of detection results of other samples in the same batch can be effectively avoided; and the accuracy and the reliability of the 21, 18 and 13 trisomic syndrome noninvasive antenatal detection are improved.

The invention discloses a second-generation sequencing method for dimolecular self-checking library preparation and hybrid capture used for trace DNA ultralow frequency mutation detection. The methodcomprises the following steps: extracting plasma free DNA, performing DNA chemical error repair, preparing a self-checking dimolecular identification code hairpin type joint, repairing plasma free DNA, connecting DNA with the joint, and performing Pre-PCR amplification, excessive hybrid capture, Post-PCR amplification, computer sequencing, data error correction, and mutation analysis and annotation. The method disclosed by the invention can efficiently realize low frequency mutation detection of plasma free DNA. DNA error repair and dual redundancy checking technology can enable the method tohave ultralow false positive rate and high sensitity while detecting trace samples, thus avoiding defects of existing plasma circulating free DNA detection methods, not only realizing cancer mutationdetection and targeted medication guidance, but also realizing early screening of genetic and birth defects of fetus.

The invention relates to the technical field of medical monitoring, and specifically relates to a monitoring method and device capable of replaying fetal-heart Doppler audio signals. The method disclosed by the invention comprises the following steps of: acquiring and storing fetal-heart monitoring signals; comparing the acquired fetal-heart monitoring signals with a judgment standard, and if the comparison result is abnormal, adding an abnormal mark in the result; when a user needs to replay the fetal-heart monitoring signals, replaying the fetal-heart monitoring signals; and carrying out judgment on the abnormal state of the fetal-heart monitoring signals by the user according to the replayed fetal-heart monitoring signals, and carrying out redefinition on the mark according to the judgment result. According to the technical scheme provided by the invention, even if doctors are not beside a fetal monitor, the doctors also can replay an audio through an audio recording module to hear fetal heart sound in follow-up time in case that the fetal heart of a fetus is subjected to a complicated heartbeat situation, and then judges whether heart rate miscalculation or real fetal-heart mutation occurs according to the beat of the audio, so that the possibility of misjudgment on fetal-heart beats is greatly reduced, and the diagnosis of the doctors is facilitated.

The invention discloses nutrient milk powder for pregnant women and a preparation method thereof, particularly milk powder which is helpful to give good birth and good care and has an auxiliary protection effect on pregnant women and fetuses, belonging to the technical field of processing of milk products. The nutrient milk powder is characterized in that every 1kg of a finished product of the nutrient milk powder for the pregnant women comprises the following components: 2000mg-8000mg of yolk globulin IgY, 300mg-1000mg of lactoferrin, 1mg-3mg of a trivalent chromium element and 1x1010cfu to 9x1011cfu of complex probiotics. The nutrient milk powder disclosed by the invention has the advantages of fully playing roles of nutrient complementation and synergistic interaction, making up the market vacancy, remarkably preventing and improving discomfort symptoms of the pregnant women in the gestation period, also enhancing the immunity and keeping full health of the pregnant women and fetuses, causing no adverse effects in aspects such as color, taste and stability, being convenient to eat and carry, and causing no harms, toxic effects or side effects to human body after being eaten normally.

The non-invasive detection of fetal chromosomal aneuploidies is demonstrated. Alleles of fetal RNA-SNPs present in a biological sample (e.g. maternal blood) containing fetal RNA are detected and quantified in order to determine the ratio of the alleles. This ratio is compared to a standard control consisting of euploid fetuses. Deviation of allele ratio indicates the presence of chromosomal aneuploidy.

The invention is directed to an immunotoxin directed at fetal AchR, wherein the immunotoxin may comprises a human Fab fragment based on a human autoantibody or human combinatorial cDNA library and may be a pseudomonas exotoxin A-based single chain Fv IT (35-scFV-ETA). The invention is further directed to method of treating a patient with soft tissue tumour comprising the step of exposing the patient to the immunotoxin of the invention.

A system for monitoring a fetus in a pregnant woman, and / or the maternal health risk for pregnancies complicated by such as pre-eclampsia and hypertensive disorders is configured to be worn by the pregnant woman, preferably so as to allow monitoring during daily life, e.g. in the form of an adhesive patch. The unit has a sound sensor, e.g. a microphone or accelerometer, to be positioned on the skin of the abdominal area so as to detect a vascular sound from umbilical arteries of the fetus or from the uterine arteries of the pregnant woman. The sound sensor is functionally connected to a processing unit which executes a processing algorithm on the captured vascular sound and extracts a signal parameter accordingly. The processing unit then communicates the signal parameter, e.g. using an audio signal, a visual display or by means of a wired or a wireless data signal.